Charles D. Blanke, MD: My Approach to Treatment of GIST
Dr. Charles D. Blanke: My Approach to Treatment of GIST
Interview by L Scott Zoeller
20110613
2011 Jul 13
OncologySTAT Editorial Team
Charles D. Blanke, MD: My Approach to Treatment of GIST
OncologySTAT Editorial Team. 2011 Jul 13, Interview by L Scott Zoeller
Abstract
Dr. Charles D. Blanke is Chief, Medical Oncology, University of British Columbia and Vice President, British Columbia Cancer Agency. OncologySTAT: Would you discuss the recent clinical findings related to duration of imatinib therapy in patients with gastrointestinal stromal tumors (GIST)?Dr. Blanke: The SSGXVIII trial tested 1 year of postoperative adjuvant therapy with imatinib mesylate vs 3 years, and the upshot is it proved the longer duration of therapy was associated with better recurrence-free...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
